"Microdosing" GLP-1s has become a marketing category. Programs sell low doses of semaglutide or tirzepatide for longevity, menopause, appetite "maintenance" or fewer side effects. The term has no medical definition, and no trial has tested it. What does exist is useful, though: label doses with clear purposes, trial results at full doses, and a first look at people who stayed on starting doses. For the drugs themselves, see our compounded semaglutide guide and our compounded tirzepatide guide.
"Microdosing" a GLP-1 means staying below the labeled doses
In practice, microdosing means one of two things. Some people stay on a starting dose for months instead of stepping up. Others take amounts smaller than any labeled dose, which usually means a compounded vial, because brand pens are made to deliver set doses.
A 2026 brief report for nurse practitioners describes what's driving it: stomach side effects at higher doses, cost, and the end of shortage-era compounding. It also lists the risks clinicians see, including dosing errors, pen manipulation, compounded vials and shared medication [8]. It's a commentary, not a study, but it captures why the trend took off.
No trial has tested microdosing for weight, wellness or aging
A PubMed search for microdosing and semaglutide, tirzepatide or GLP-1, run for this update, returned letters, commentaries, a narrative review and one records study, but no randomized trial of microdosing [10]. Programs selling it for longevity have no trial to point to.
The closest thing to data is that records study. Researchers used health records to find people who kept refilling only the starting dose for at least six months: 814 on semaglutide 0.25 mg and 1,016 on tirzepatide 2.5 mg. At 12 months, average weight change was 2.2% on semaglutide and 5.5% on tirzepatide [9]. The authors work for nference, a data company that collaborates with drug makers, and they say their findings can't establish intentional microdosing.
Those bars come from different kinds of studies and different time frames, so don't read them as a head-to-head. They do show the gap in scale. The doses that produced double-digit weight loss in trials are several times higher than the doses people call microdoses.
The low doses on the labels exist to start treatment
Both brand labels begin low on purpose. Wegovy's injection starts at 0.25 mg once weekly for weeks 1 to 4, then steps through 0.5 mg, 1 mg and 1.7 mg before a maintenance dose from week 17 [1]. Zepbound starts at 2.5 mg once weekly for four weeks and says that dose "is for treatment initiation and is not approved as a maintenance dosage" [2].
The reason is the same on both labels: the step-up exists to reduce the risk of gastrointestinal side effects. So the starting doses are tolerability steps, not the doses the drugs were approved to work at.
| Drug | Label starting dose | Maintenance doses tested (trial result) | Sub-label "microdose" | Evidence |
|---|---|---|---|---|
| Semaglutide injection (Wegovy) | 0.25 mg weekly, weeks 1–4 | 2.4 mg weekly: −14.9% at 68 weeks vs −2.4% on placebo (STEP 1) [4]; label also allows 1.7 mg | Below 0.25 mg, or 0.25 mg kept long term | No trial |
| Tirzepatide injection (Zepbound) | 2.5 mg weekly, weeks 1–4 | 5, 10, 15 mg weekly: −15.0%, −19.5%, −20.9% at 72 weeks vs −3.1% on placebo (SURMOUNT-1) [5] | Below 2.5 mg, or 2.5 mg kept long term | No trial |
| Semaglutide tablets (Wegovy pill) | 1.5 mg daily for 30 days | 25 mg daily: −13.6% at 64 weeks vs −2.2% on placebo (OASIS 4) [6] | Not a common pitch | No trial |
| Any GLP-1 "microdose" | n/a | n/a | Any dose below the label | One records study of starting doses; no randomized trial |
Label doses from the Wegovy and Zepbound prescribing information on DailyMed. Trial results as published; see sources.
Microdosing semaglutide usually means living at the 0.25 mg step
Low-dose semaglutide pitches usually point to the 0.25 mg starting dose. The trial that earned Wegovy its weight-loss approval tested 2.4 mg weekly. In STEP 1, 1,961 adults with overweight or obesity lost an average of 14.9% of body weight at 68 weeks, against 2.4% on placebo [4].
Brand pens are made to give the labeled doses. Ozempic and Wegovy pens deliver fixed amounts, and their labels list only those doses. That's why most microdose programs use compounded vials, and why dose accuracy becomes the central question. The Wegovy pill is a separate story, with its own doses and trials, covered in the oral semaglutide guide.
Microdosing tirzepatide follows the same pattern
Tirzepatide's labeled maintenance doses are 5, 10 and 15 mg. In SURMOUNT-1, even the lowest of those, 5 mg weekly, produced an average 15.0% weight loss at 72 weeks [5]. Anything below 2.5 mg is outside both the label and the trials. The guide to microdosing tirzepatide covers that drug in more depth.
The longevity pitch borrows a heart trial that tested full doses
Longevity marketing often cites SELECT. In that trial, 17,604 adults with heart disease and overweight or obesity, but without diabetes, took semaglutide 2.4 mg or placebo. Major cardiovascular events fell from 8.0% to 6.5% of patients, a hazard ratio of 0.80 [7]. It's a real benefit. But SELECT tested the full 2.4 mg dose, in people with existing heart disease, and it measured heart attacks, strokes and cardiovascular death, not aging.
A trial now recruiting will test semaglutide, tirzepatide and metformin on a DNA-methylation measure of biological age in adults with obesity. It uses standard step-up schedules, not microdoses, and runs 24 weeks [11]. Even when it reports, it won't show that low doses slow aging.
If longevity is your goal, the evidence questions are similar for the other off-label options. See metformin for longevity and our rapamycin guide.
The biggest risks are dose accuracy and product quality
Smaller doses don't make compounded vials safer to measure. They can make it harder. FDA has received multiple reports of adverse events, some requiring hospitalization, that may be related to dosing errors with compounded injectable semaglutide, from patients measuring wrong amounts and sometimes from clinicians miscalculating them [3].
- Vial strength varies between pharmacies, so the same milligram dose is a different volume from one vial to another. FDA urges patients to ask their prescriber or compounder how to measure their dose.
- Multi-dose vials expire after 28 days of use, per FDA, even if the compounder's label says longer. A tiny weekly dose means many people won't finish a vial in that window.
- Salt forms such as semaglutide sodium or acetate are different active ingredients, and FDA knows of no lawful basis for compounding them.
- Warm deliveries shouldn't be used, according to FDA, because heat can affect quality.
Those points all come from FDA's page on unapproved GLP-1 drugs [3]. The 28-day rule deserves emphasis here. A microdose program that ships one vial to last months is asking you to keep using it well past the window FDA recommends.
The labels already allow a slower pace when a dose isn't tolerated
There's a label-backed version of "going slow." Wegovy's label says that if a patient doesn't tolerate a dose during the step-up, prescribers can consider delaying the next increase by four weeks [1]. Zepbound's label sets a minimum of four weeks per step, not a maximum, so a prescriber can hold a dose longer [2].
That's a prescriber's call, made dose by dose with your side effects in view. It's different from a program that sells a fixed low-dose plan to everyone.
What microdose programs charge
Microdose plans are often priced a little below full-dose plans at the same program, though not always. Some require a minimum commitment. Here is what each program publishes; AgelessRx, Shed and Midi Health show how differently the same idea can be billed.
| Provider | Drug | Monthly cost | Billing or minimum |
|---|---|---|---|
| LttlPartner | Semaglutide; tirzepatide | Semaglutide $149/mo; tirzepatide $149/mo | Monthly or prepaid |
| bmiMDPartner | Semaglutide; tirzepatide | Semaglutide $159/mo; tirzepatide $249/mo | Month to month, or prepaid |
| ShedPartner | Semaglutide; tirzepatide | Semaglutide $161.42/mo; tirzepatide $215.58/mo | Monthly, 2-month minimum |
| Enhance MD | Tirzepatide | $189/mo | 3-month prepay minimum |
| Luvo HealthPartner | Semaglutide; tirzepatide | Semaglutide $193.92/mo; tirzepatide $193.92/mo | Every 4 weeks |
| AgelessRx | Semaglutide; tirzepatide (with glycine) | Semaglutide —; tirzepatide $159/mo | Tirzepatide renews every 2 months; semaglutide intro needs a 4-month plan |
| CoreAge RxPartner | Semaglutide; tirzepatide | Shown at checkout | Plan chosen at checkout |
| Midi Health | GLP-1 (not specified) | Priced per week | Weekly pricing for eligible patients |
Alphabetical. Prices from each provider's own site. Brightmeds and Found mention microdosing without publishing a price.
Also offered by (no standing monthly price published): Maximus.
Compare the true monthly figure at the program, not the first-month offer, and check how long you're committing to. Then compare it with that program's full-dose plan. Sometimes the gap is small enough that the label route makes more sense.
Weighing programs on price? The compounded semaglutide providers lineup sets 88 of them side by side, each with its true monthly cost.